News

Her Majesty the Queen will be remembered for her devotion and commitment to the Commonwealth for many years to come. We pay tribute to the Queen’s 70 years of service. The Queen’s dedication to [...]

The ALLG trial BM12 CAST has been accepted for publication as an abstract at EHA. Congratulations to the Chief Investigators A/Prof David Curtis and Dr Sushrut Patil, and the trial team.

We are all extremely saddened to announce that our respected colleague and friend Associate Professor James D'Rozario MBBS, FRACP, FRCPA, Senior Staff Specialist and Clinical Director, Department [...]

Clinical trials generate the evidence needed to help close the care gap and improve global practices in cancer care. That’s what we do everyday at the Australasian Leukaemia and Lymphoma Group [...]

A preeminent expert in blood cancer, Professor Mark Hertzberg who has dedicated his life and career to advancing the medicine and science of leukaemia, lymphoma and other blood disorders in [...]

ALLG and HSANZ welcomes the Report tabled in Parliament 25/11/21 on ‘The New Frontier – Delivering better health for all Australians: Inquiry into approval processes for new drugs and novel [...]

Through partnerships and collaborations that we are able to create better treatments and better lives for blood cancer patients.

The Consumer Representative Panel is an invaluable source of information to members of the ALLG

Coming up to the end of the year, we would like to thank Natalia Racomelara and her family for their wonderful support.

The NBCR and Biobank was established by the ALLG in 2012.

Wow, what a year it’s been!

The European Hematology Association closed its annual congress on Sunday, June 21.

The European Hematology Association closed its annual congress on Sunday, June 21.

The European Hematology Association closed its annual congress on Sunday, June 21.

The European Hematology Association closed its annual congress on Sunday, June 21.

The European Hematology Association closed its annual congress on Sunday, June 21.

The European Hematology Association closed its annual congress on Sunday, June 21.

The ALLG is supporting an “EHA Game-Changers” webcast on Thursday, July 2.

The ALLG HD10 clinical trial reached the significant milestone of recruiting 100 patients to this important international cooperative trial.

New research findings on how early genetic changes in blood and bone marrow cells can lead to the development of blood cancer.

Warmest congratulations to Prof Joy Ho and Prof Andrew Roberts, long-time ALLG leaders who were both yesterday appointed Members of the Order of Australia in the Queen’s Birthday Honours.

The ALLG hosted a roundtable discussion yesterday in Melbourne, led by Professor Peter Borchmann of the University of Cologne and co-chairman of the German Hodgkin Study Group (GHSG).

ALLG will take part in Australia’s first Blood Cancer Taskforce, announced yesterday by Minister Greg Hunt and established in collaboration with the Leukaemia Foundation of Australia, which [...]

This week, ALLG’s National Blood Cancer Registry (NBCR) contributed to a new study on acute myeloid leukaemia (AML) published in the Journal of Clinical Oncology.

Cara Markovic joins the ALLG with over 15 years of experience in the medical device industry. A PhD qualified physiologist by training, she has held various scientific and marketing roles in [...]

On Monday 11 June, the Chairman of the ALLG, Mr Peter T Kempen was announced as an honorary Member (AM) in the general division of the Order of Australia honours for significant service to the [...]

The Australasian Leukaemia and Lymphoma Group (ALLG) held its May 2018 Scientific Meeting (SM) in Melbourne with 270 members in attendance.

Late last year the ALLG welcomed the release of the Select Committee report into Funding for Research into Cancers with Low Survival Rates, calling on the Federal Government to make research into [...]

This year, almost 16,000 Australians will begin a long and gruelling journey with blood cancer. Decades of research have led to vastly improved outcomes for blood cancer patients with survival [...]

The Australasian Leukaemia & Lymphoma Group (ALLG) welcomed the November 2017 release of the Select Committee Report into funding for research into cancers with low survival rates.

Professor Mark Hertzberg recently retired as Chair of The Australasian Leukaemia & Lymphoma Group (ALLG) Scientific Advisory Committee (SAC). Prof Hertzberg, who took the role as Chair in 2010 [...]